Personalized Medicine Experts Say the Future of Healthcare is Here Today
NEW YORK, Jan. 28 /PRNewswire/ — The treatment of illness has traditionally been based on the law of averages – what works best for the largest number of patients. As a result, billions of dollars are spent every year on treatments that could be ineffective or even harmful for some patients. What if doctors could tell with a simple test which course of treatment would be best for a particular patient? As recently as a decade ago, this would have seemed like science fiction. But thanks to recent advances in molecular diagnostics, “personalized medicine” – which allows physicians to tailor treatment to a patient based upon defined characteristics – is a reality today, according to a panel of experts who will be discussing opportunities and obstacles of personalized medicine at an exclusive media event hosted by QIAGEN.
QIAGEN, a worldwide leader in molecular diagnostic technologies, will host a panel discussion with experts in the field of personalized medicine, including Edward Abrahams, Ph.D., executive director of the Personalized Medicine Coalition (PMC); Nancy Roach, co-founder and Board Chair of C3: Colorectal Cancer Coalition; and Peer Schatz, CEO of QIAGEN, whose tests and tools are being used by physicians, leading researchers and many of the largest pharmaceutical companies to determine patients’ potential responses to drug treatments based on specific genetic markers. The event, which will be open exclusively to media, will be held at the Four Seasons Hotel in New York on February 11, 2010.
“We are honored to have such a distinguished panel to address many of the facets of personalized medicine, including public policy, science, and patient care. With the nation focused on healthcare reform, the timing of this event couldn’t be better,” said Schatz. “For instance, some of the most popular treatments for cardiovascular and neurological diseases, and most prominently cancer, are effective in only about 60 percent of patients. That leaves a significant portion of the population searching for a treatment that works for them, often at considerable expense. Personalized medicine can dramatically improve the success rate, while significantly reducing unnecessary and ineffective treatments.”
The U.S. Food and Drug Administration (FDA) has already identified 32 different genomic biomarkers in current product labeling of various drugs, which can be used to leverage a patient’s genetic information in order to plan a personalized course of treatment. There are currently diagnostic tests to help improve treatment for certain types of cancer, improve matches for organ transplants, and avoid serious side effects or help to find the right dosage of drugs such as Warfarin. These advances are just the tip of the iceberg. The market for personalized medicine is growing by 24 percent annually and has already reached $13 billion (USD), according to a 2009 industry report by Bain & Company.
“In medicine, one size does not fit all. Numerous advances in molecular diagnostics have made it possible to better target drugs to selected patients based on defined biomarkers and thereby also avoiding unnecessary adverse affects,” PMC’s Abrahams said. “But it is important that patients understand their treatment options and know what questions to ask. This panel discussion will be another way to educate the public about the emerging promise of personalized medicine.”
As an example of what is currently being done, two of QIAGEN’s research tests can detect the presence of biomarkers K-RAS and B-RAF in certain cancer patients. Identifying any mutations of the K-RAS gene, which is also indicative for other cancers, enables doctors to assess whether patients suffering from metastatic colorectal cancer may benefit from treatment with the most common, and potentially cost-prohibitive anti-EGFR drugs. Another QIAGEN assay can detect a specific gene mutation that is associated with AIDS patients who may be susceptible to adverse reactions to the commonly-prescribed drug Abacavir. Knowing patients have this mutation allows their doctors to choose a different course of treatment.
“Every day we are seeing more evidence of improved drug efficacy through ‘companion diagnostics’ – or testing a patient’s genetic make-up before selecting a course of treatment,” said Nancy Roach, a cancer survivor, patient advocate, and co-founder and Board Chair for C3: Colorectal Cancer Coalition. “For illnesses such as cancer, where time is a luxury we don’t have, the ability to tailor treatment to a specific person’s genome, rather than relying on time consuming trial-and-error, can mean the difference between life and death.”
The personalized medicine panel discussion is open to media only. Attendance will be limited. For media interested in attending or for more information about the event, please contact Melissa Arnoff at firstname.lastname@example.org or 202-973-1336.
QIAGEN, N.V., a Netherlands holding company, is the leading global provider of assay technologies. Sample technologies are used to isolate and process DNA, RNA and proteins from biological samples such as blood or tissue. Assay technologies are used to make such isolated biomolecules visible. QIAGEN has developed and currently markets more than 500 sample and assay products as well as automated solutions for such consumables. The company provides its products to molecular diagnostics laboratories, academic researchers, pharmaceutical and biotechnology companies, and applied testing customers for purposes such as forensics, animal or food testing and pharmaceutical process control. QIAGEN’s assay technologies include one of the broadest panels of molecular diagnostic tests available worldwide. This panel includes the digene HPV Test, which is regarded as a “gold standard” in testing for high-risk types of human papillomavirus (HPV), the primary cause of cervical cancer, as well as a broad suite of solutions for infectious disease testing and companion diagnostics. QIAGEN employs more than 3,400 people in over 30 locations worldwide. Further information about QIAGEN can be found at http://www.qiagen.com.
About the Personalized Medicine Coalition
The Personalized Medicine Coalition (PMC), representing a broad spectrum of academic, industrial, patient, provider, and payer communities, seeks to advance the understanding and adoption of personalized medicine concepts and products for the benefit of patients. For more information, please visit www.PersonalizedMedicineCoalition.org.
About the Colorectal Cancer Coalition
C3: Colorectal Cancer Coalition is a nonprofit, nonpartisan advocacy organization that fights colorectal cancer through research, empowerment and access. C3 pushes for research to improve screening, diagnosis, and treatment of colorectal cancer; for policy decisions that make the most effective colorectal cancer prevention and treatment available to all; and for increased awareness that colorectal cancer is preventable, treatable, and beatable. Nationally headquartered near Washington D.C., C3 supports the work of research and grassroots advocates throughout the United States. For more information, visit http://FightColorectalCancer.org.
Safe Harbor Statement
Statements regarding QIAGEN contained in this release that are not historical facts are forward-looking statements, including statements about our products, markets, strategy, and operating results. Such statements are based on current expectations that involve risks and uncertainties including, but not limited to, those associated with: management of growth and international operations (including currency fluctuations and logistics); variability of our operating results; commercial development of our markets (including applied testing, clinical and academic research, proteomics, women’s health/HPV testing and molecular diagnostics); our relationships with customers, suppliers and strategic partners; competition; changes in technology; fluctuations in demand; regulatory requirements; identifying, developing and producing integrated products differentiated from our competitors’ products; market acceptance of our products; and integration of acquired technologies and businesses. For further information, refer to our filings with the SEC, including our latest Form 20-F. Information in this release is as of the date of the release, and we undertake no duty to update this information unless required by law.